Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Pain. 2020 Sep 1;161(9):2179–2190. doi: 10.1097/j.pain.0000000000001905

Figure 5.

Figure 5.

Gastrointestinal transit is not reduced by acute A3AR agonism with MRS5980. (A) Amount of 70 kDA FITC-dextran in small intestine segments 15 minutes after MRS5980 or vehicle dosing and 40 minutes after oral gavage of the marker. Two-way ANOVA, interaction: F(9,92) = 0.8676; P = 0.9553; GI Section: P = 0.0010; Treatment: P = 0.4584 (B) Amount of 70,000 kDa FITC-dextran in serum samples of 15 minutes after MRS5980 or vehicle dosing and 40 minutes after oral gavage of the marker (unpaired t test, P = 0.3955 MRS5980 compared to vehicle.) Each value is the mean ± S.E.M. of 6 rats. ANOVA, analysis of variance.